Hematoporphyrin derivative (HpD) photoradiation therapy (PRT) is the treatment of solid tumors by a protocol that consists of the intravenous administration of hematoporphyrin derivative followed 2 or 3 days later by a localized exposure of the tumor to red light. The preferential retention of hematoporphyrin derivative in malignant tissue compared to adjacent normal tissue, and the generation of cytotoxic oxygen species by porphyrins when illuminated with visible light account for the effectiveness of photoradiation therapy. Initial results on the clinical use of photoradiation therapy for the treatment of various types of solid tumors have been encouraging. However, there still remains a significant lack of information pertaining to many of the cellular and tissue kinetics related to porphyrin induced photodynamic action. In addition, there has been only minimal preclinical evaluation of the treatment parameters utilized in clinical photoradiation therapy. The research described in this proposal is designed to examine treatment parameters as well as study basic mechanisms related to porphyrin photoradiation therapy. Both HpD and the active component of HpD (Photofrin II) are used clinically and, therefore, both drugs will be investigated in this proposal. In-vivo procedures will be utilized to examine the parameters of wavelength of delivered light and dose rate of delivered light as they relate to photoradiation induced tumor response. Determination of the effect of general and local anesthesia on the efficiency of porphyrin photoradiation therapy will also be performed. Quantitative studies will also be performed to determine the effect of vasoactive agents on porphyrin uptake in tumor tissue. In-vivo procedures will be utilized to document the oncogenic potential of PRT, examine possible repair properties of porphyrin photoradiation and compare the sensitivity of normal and DNA repair deficient human fibroblasts exposed to porphyrin photosensitization. In addition, studies will be performed to compare the porphyrin uptake kinetics and photosensitization properties of bovine endothelial and smooth muscle cells. These studies should enhance the understanding and efficacy of photoradiation therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA031230-05
Application #
3169508
Study Section
Radiation Study Section (RAD)
Project Start
1982-03-01
Project End
1988-02-29
Budget Start
1986-03-01
Budget End
1987-02-28
Support Year
5
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Children's Hospital of Los Angeles
Department
Type
DUNS #
094878337
City
Los Angeles
State
CA
Country
United States
Zip Code
90027
Ferrario, Angela; Lim, Sophia; Xu, Frank et al. (2011) Enhancement of photodynamic therapy by 2,5-dimethyl celecoxib, a non-cyclooxygenase-2 inhibitor analog of celecoxib. Cancer Lett 304:33-40
Ferrario, Angela; Luna, Marian; Rucker, Natalie et al. (2011) Pro-apoptotic and anti-inflammatory properties of the green tea constituent epigallocatechin gallate increase photodynamic therapy responsiveness. Lasers Surg Med 43:644-50
Ferrario, Angela; Gomer, Charles J (2010) Targeting the tumor microenvironment using photodynamic therapy combined with inhibitors of cyclooxygenase-2 or vascular endothelial growth factor. Methods Mol Biol 635:121-32
Luna, Marian; Ferrario, Angela; Wong, Sam et al. (2010) Identification of MAP kinase pathways involved in COX-2 expression following photofrin photodynamic therapy. Methods Mol Biol 635:47-63
Ferrario, Angela; Gomer, Charles J (2010) Targeting the 90 kDa heat shock protein improves photodynamic therapy. Cancer Lett 289:188-94
Luna, Marian; Wong, Sam; Ferrario, Angela et al. (2008) Cyclooxygenase-2 expression induced by photofrin photodynamic therapy involves the p38 MAPK pathway. Photochem Photobiol 84:509-14
Ferrario, Angela; Rucker, Natalie; Wong, Sam et al. (2007) Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response. Cancer Res 67:4989-95
Bozkulak, Ozguncem; Wong, Sam; Luna, Marian et al. (2007) Multiple components of photodynamic therapy can phosphorylate Akt. Photochem Photobiol 83:1029-33
Ferrario, Angela; Fisher, Anita M; Rucker, Natalie et al. (2005) Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res 65:9473-8
Ferrario, Angela; Chantrain, Christophe F; von Tiehl, Karl et al. (2004) The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res 64:2328-32

Showing the most recent 10 out of 14 publications